262 related articles for article (PubMed ID: 32389945)
41. [Antibody therapy for acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
[TBL] [Abstract][Full Text] [Related]
42. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
Al-Salama ZT
Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
[TBL] [Abstract][Full Text] [Related]
43. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
Brivio E; Chantrain CF; Gruber TA; Thano A; Rialland F; Contet A; Elitzur S; Dalla-Pozza L; Kállay KM; Li CK; Kato M; Markova I; Schmiegelow K; Bodmer N; Breese EH; Hoogendijk R; Pieters R; Zwaan CM
Br J Haematol; 2021 Jun; 193(6):1172-1177. PubMed ID: 33529389
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Jabbour EJ; DeAngelo DJ; Stelljes M; Stock W; Liedtke M; Gökbuget N; O'Brien S; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS; Kantarjian HM
Cancer; 2018 Apr; 124(8):1722-1732. PubMed ID: 29381191
[TBL] [Abstract][Full Text] [Related]
45. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Bhojwani D; Sposto R; Shah NN; Rodriguez V; Yuan C; Stetler-Stevenson M; O'Brien MM; McNeer JL; Quereshi A; Cabannes A; Schlegel P; Rossig C; Dalla-Pozza L; August K; Alexander S; Bourquin JP; Zwaan M; Raetz EA; Loh ML; Rheingold SR
Leukemia; 2019 Apr; 33(4):884-892. PubMed ID: 30267011
[TBL] [Abstract][Full Text] [Related]
46. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Jabbour E; Advani AS; Stelljes M; Stock W; Liedtke M; Gökbuget N; Martinelli G; O'Brien S; White JL; Wang T; Luisa Paccagnella M; Sleight B; Vandendries E; DeAngelo DJ; Kantarjian HM
Am J Hematol; 2019 Apr; 94(4):408-416. PubMed ID: 30623490
[TBL] [Abstract][Full Text] [Related]
47. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
48. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
49. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
Ohana Z; Serraes S; Elder C; Katusa N
J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
[TBL] [Abstract][Full Text] [Related]
50. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
51. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
[TBL] [Abstract][Full Text] [Related]
52. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
[TBL] [Abstract][Full Text] [Related]
53. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.
Rytting M; Triche L; Thomas D; O'Brien S; Kantarjian H
Pediatr Blood Cancer; 2014 Feb; 61(2):369-72. PubMed ID: 24000241
[TBL] [Abstract][Full Text] [Related]
54. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
[TBL] [Abstract][Full Text] [Related]
55. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Papayannidis C; Sartor C; Dominietto A; Zappone E; Arpinati M; Marconi G; Cristiano G; Nanni J; Parisi S; Barbato F; Paolini S; Soverini S; Terragna C; Robustelli V; Testoni N; Chirumbolo G; Curti A; Cavo M; Bonifazi F
Hematol Oncol; 2021 Oct; 39(4):580-583. PubMed ID: 33963566
[No Abstract] [Full Text] [Related]
56. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V; Brivio E; van Tinteren H; Rheingold SR; Leahy A; Vormoor B; O'Brien MM; Rubinstein JD; Kalwak K; De Moerloose B; Jacoby E; Bader P; López-Duarte M; Goemans BF; Locatelli F; Hoogerbrugge P; Calkoen FG; Zwaan CM
Leukemia; 2023 Jan; 37(1):53-60. PubMed ID: 36310183
[TBL] [Abstract][Full Text] [Related]
57. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
58. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes M; Raffel S; Alakel N; Wäsch R; Kondakci M; Scholl S; Rank A; Hänel M; Spriewald B; Hanoun M; Martin S; Schwab K; Serve H; Reiser L; Knaden J; Pfeifer H; Marx J; Sauer T; Berdel WE; Lenz G; Brüggemann M; Gökbuget N; Wethmar K
J Clin Oncol; 2024 Jan; 42(3):273-282. PubMed ID: 37883727
[TBL] [Abstract][Full Text] [Related]
59. Sequential Therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Primary Refractory Acute Lymphoblastic Leukemia: A Case Report.
Uchida E; Kurata T; Komori K; Kobayashi J; Kubota N; Sakashita K
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1228-e1230. PubMed ID: 34001796
[TBL] [Abstract][Full Text] [Related]
60. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.
Moribe T; Xu L; Tajima K; Yonemoto N
Future Oncol; 2023 Jun; 19(19):1343-1356. PubMed ID: 37212792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
